Biodexa Pharmaceuticals (BDRX)
NASDAQ: BDRX
· Real-Time Price · USD
1.43
-0.03 (-2.05%)
At close: May 01, 2025, 3:59 PM
1.40
-1.75%
After-hours: May 01, 2025, 04:16 PM EDT
-2.05% (1D)
| Bid | 1.06 |
| Market Cap | 2.38K |
| Revenue (ttm) | 83K |
| Net Income (ttm) | -6.82M |
| EPS (ttm) | -13.29 |
| PE Ratio (ttm) | -0.11 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.51 |
| Volume | 33,096 |
| Avg. Volume (20D) | 1,940,355 |
| Open | 1.49 |
| Previous Close | 1.46 |
| Day's Range | 1.40 - 1.49 |
| 52-Week Range | 1.14 - 74.00 |
| Beta | 1.71 |
About BDRX
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 7, 2015
Employees 13
Stock Exchange NASDAQ
Ticker Symbol BDRX
Website https://www.biodexapharma.com
2 weeks ago
+12.74%
Biodexa Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
1 month ago
+15.84%
Biodexa Pharmaceuticals shares are trading higher after the company announced it is on track to initiate Phase 3 trial in FAP next quarter.
